Taken together, the key evidence obtained during the current study suggests that 1,25(OH)2D3/VDR acts to stimulate the recovery from SLE symptoms by downregulating Skp2 and upregulating the p27, highlighting a promising novel therapeutic target for future SLE treatment. Here, SKP2 is linked to systemic lupus erythematosus.